Acorda Expands Pipeline With Neuronex And New Ampyra Indications
By
Lisa LaMotta / Email the Author / “The Pink Sheet” DAILY Feb. 16, 2012
Word Count: 964 / Article # 14120216002
Executive Summary
Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it’s pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.